预约演示
更新于：2025-11-24
Sevelamer Carbonate
碳酸司维拉姆
更新于：2025-11-24
概要
基本信息
药物类型 聚合物 |
别名 Renvela(TN)、sevelamer、Sevelamer carbonate (USAN) + [7] |
作用方式 调节剂 |
作用机制 Phosphates 调节剂(磷酸盐 调节剂) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2007-10-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS号845273-93-0 |
关联
53
项与 碳酸司维拉姆 相关的临床试验PACTR202408492665945
The Adjuvant Role of Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Patients
IRCT20210720051946N7
Evaluation the effect of adding Sevelamer to the standard treatment of aluminum phosphide poisoning patients, referred to Tehran's Luqman Hospital, a preliminary studyon mortalit
CTR20230498
一项在健康受试者中评价含钙的磷结合剂醋酸钙片和非含钙的磷结合剂碳酸司维拉姆片对德度司他片的药动学影响的单中心、随机、开放、三周期交叉的I期临床研究
100 项与 碳酸司维拉姆 相关的临床结果
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的转化医学
登录后查看更多信息
100 项与 碳酸司维拉姆 相关的专利（医药）
登录后查看更多信息
416
项与 碳酸司维拉姆 相关的文献（医药）2025-10-01TRANSPLANTATION PROCEEDINGS
Characteristics of Mineral Bone Disease Profile in Kidney Transplant Recipients – A 9-Year Retrospective Cohort Study at a Tertiary Center
Article
作者: Leon, Guo Jian ; Em, Jun Min ; Lim, Soo Kun ; Jalalonmuhali, Maisarah ; Rozi, Nur Raziana ; Lee, Yee Wan
BACKGROUND:
The progression of chronic kidney disease (CKD) into end-stage kidney disease and the eventual kidney transplantation is linked to substantial changes in bone mineral metabolism, predisposing to bone-related complications, including osteoporosis and fractures. Understanding the bone profile in kidney transplant recipients could improve post-transplant care and long-term outcomes.
METHODS:
This retrospective study at the University Malaya Medical Centre (UMMC) involved all kidney transplant recipients from January 2015 to December 2023. Patients without baseline serum intact parathyroid hormone levels or who had graft failure within 1 year were excluded. All baseline characteristics, medications, and pre- and post-transplant bone mineral profiles were collected from electronic medical records (EMRs) and analyzed using Statistical Package for the Social Sciences version 29.0.2.
RESULTS:
A total of 179 patients were included, with a mean age of 40.6 ± 11.0 years old (57% men). The median dialysis vintage was 18 (interquartile range [IQR] = 36), with 19% undergoing pre-emptive transplants. Before the transplant, 57% of the patients received calcium carbonate, 51.4% were on vitamin D receptor analogues (VDRAs), 26.3% were on sevelamer, 5.6% were on cinacalcet, 2.2% were on lanthanum, and 0.6% were on sucroferric oxyhydroxide. All patients received induction methylprednisolone during the transplant. At 1 year post-transplant, 90% of the patients remained on prednisolone at a median dose of 5.0 mg. Parathyroidectomy was performed on two patients (1.1%) before transplant and another two (1.1%) after transplant. No patient had a fracture post-transplantation during the study period. Biochemically, mean serum intact parathyroid hormone (iPTH), calcium, phosphate, and hemoglobin were significantly improved from pre-transplant to 2 years post-transplant (P < .001), with serum iPTH and calcium showing improvement as early as 3 months and maintained thereafter. Both serum phosphate and hemoglobin levels continuously showed improvement up to 2 years post-transplant (P < .05).
CONCLUSIONS:
Our study showed significant improvements in biochemical bone profile and hemoglobin levels as early as 3 months post-transplant, which had continued to improve or maintain for up to 2 years post-transplant.
2025-09-01JOURNAL OF RENAL NUTRITION
Gastrointestinal Mucosal Cell Injury Caused by Sevelamer Crystals: Case Series and Literature Review
Review
作者: Ali, Umair ; Singh, Manisha ; Elkalashy, Ahmed ; Karakala, Nithin ; Elbahnasawy, Enas ; Rainwater, Randall R
In end-stage kidney disease (ESKD), hyperphosphatemia occurs secondary to decreased renal elimination with continued intestinal absorption of dietary phosphate. Even in chronic kidney disease, glomerular filtration rate lower than 30 mL/min markedly decreases the filtration of inorganic phosphate and increases its serum level. Sevelamer, a noncalcium phosphate binder, is commonly used to control hyperphosphatemia. Available in 2 forms, sevelamer hydrochloride and sevelamer carbonate, it absorbs phosphate in the gastrointestinal tract and is known to have minimal adverse effects. These are limited to nausea, vomiting, flatulence, and metabolic acidosis, with infrequent significant adverse outcomes. We present a series of 2 patients with ESKD on sevelamer, with lower gastrointestinal bleeding and endoscopic findings of colonic mucosal injuries with histopathological findings of sevelamer crystals deposition. Although reported in gastrology literature, nephrology reports show a paucity of discussion around this increasingly common adverse effect and the need for vigilance in ESKD.
2025-09-01INTERNATIONAL IMMUNOPHARMACOLOGY
Pharmacologic modulation of systemic inorganic phosphate levels restores the impaired phagocytosis of Kupffer cells and improves liver function in murine models of chronic liver failure
Article
作者: Deng, Zhi-Qiang ; Liang, Qing-Rong ; Liu, Yue ; Wang, Le-Ran ; Liao, Zi-Qiang ; Zhang, Chun-Bo ; Tang, Qun ; Chen, Ze-Ning ; Zhou, Bin-Quan ; Xie, Xian-Bing
Chronic liver disease induced by various etiologies (ethanol, viruses, etc.) impairs macrophage phagocytosis. This study demonstrated that such impairment could be alleviated by systemic weak phosphate stress in vitro and in vivo. A cell model of ethanol-induced damage was established by incubating the RAW 264.7 cell line in a low-phosphate medium, and the phagocytic capacity of the injured cells was increased, as evidenced by their increased ability to engulf Escherichia coli and fluorescent microspheres. The transcriptomic analysis combined with laboratory validation by qPCR and Western blotting identified the PI3K-Akt signaling pathway and RAC3 protein as potential contributors. The expression of FcγR was inhibited after injury, but low Pi stress increased its expression to normal levels for foreign body recognition. Moreover, actin polymerization was also increased, which is beneficial for phagosome formation. In both alcohol- and DEN-induced models of chronic liver injury, alcohol exposure led to a decreased phagocytic capacity of liver macrophages (Kupffer cells), which was mitigated by the oral administration of sevelamer (5 % w/w). Immunohistochemical results confirmed the findings from the cellular experiments, revealing consistent expression patterns of FcγR, RAC3, and PI3K-Akt. Furthermore, damage to liver function was ameliorated in both models. In conclusion, these results indicate that the weak phosphate stress induced by sevelamer has therapeutic potential to reverse the impairment of phagocytosis caused by liver injury.
93
项与 碳酸司维拉姆 相关的新闻（医药）2025-11-23
·信狐药迅
信使RNA疫苗核酸药物申请上市
2025-11-19
·摩熵医药
临床3期临床申请优先审批申请上市
2025-11-17
申请上市高管变更核酸药物
100 项与 碳酸司维拉姆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病-矿物质和骨骼疾病 | 欧盟 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 冰岛 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 列支敦士登 | 2015-01-15 | |
| 慢性肾病-矿物质和骨骼疾病 | 挪威 | 2015-01-15 | |
| 高磷血症 | 欧盟 | 2009-06-09 | |
| 高磷血症 | 冰岛 | 2009-06-09 | |
| 高磷血症 | 列支敦士登 | 2009-06-09 | |
| 高磷血症 | 挪威 | 2009-06-09 | |
| 慢性肾病 | 美国 | 2007-10-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 终末期肾脏病 | 临床3期 | 法国 | 2010-10-01 | |
| 继发性甲状旁腺功能亢进症 | 临床3期 | 美国 | 2010-04-01 | |
| 心血管疾病 | 临床2期 | 英国 | 2009-02-01 | |
| 2型糖尿病 | 临床阶段不明 | 丹麦 | 2014-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 44 | (TPOXX: Oral Antiviral) | 鬱襯積網鏇壓網廠範艱(艱窪醖鬱襯夢築簾餘鬱) = 壓餘齋觸遞醖構齋襯鬱 壓壓獵遞糧鏇醖醖餘鏇 (衊鑰願襯衊顧選鑰淵築, 39.6) 更多 | - | 2024-10-09 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | 鏇衊廠構鬱蓋築憲獵廠(糧鹽淵齋簾願鏇繭鹹願) = 窪繭觸構構構壓齋醖構 蓋繭鏇構壓鑰鹹鬱網簾 (蓋選廠廠鑰鹹鬱鏇憲觸, 糧夢蓋齋淵觸範鏇鑰範 ~ 鏇範築膚淵構獵遞鬱齋) 更多 | ||||||
临床3期 | 286 | 網遞願蓋鏇襯簾衊繭鏇(憲淵糧衊網醖衊繭製築) = 鏇築鹽糧顧廠構積憲壓 醖鏇獵網鏇夢鏇夢糧廠 (獵襯襯憲膚積艱遞艱範 ) | 积极 | 2023-07-20 | |||
網遞願蓋鏇襯簾衊繭鏇(憲淵糧衊網醖衊繭製築) = 夢廠顧鏇餘鏇鑰襯選鹹 醖鏇獵網鏇夢鏇夢糧廠 (獵襯襯憲膚積艱遞艱範 ) | |||||||
临床4期 | 172 | (Tenapanor w/Sevelamer) | 蓋積餘廠構構餘構製鏇 = 餘膚遞餘壓鏇衊製壓壓 範鏇簾鏇艱製餘鏇鹹築 (襯鑰積鬱網製醖鏇壓鏇, 遞鹽襯衊遞糧積願顧遞 ~ 築築淵積獵壓鬱觸顧憲) 更多 | - | 2023-03-29 | ||
(Sevelamer w/Tenapanor) | 蓋積餘廠構構餘構製鏇 = 廠選壓遞廠築獵襯鹹廠 範鏇簾鏇艱製餘鏇鹹築 (襯鑰積鬱網製醖鏇壓鏇, 顧築窪醖窪蓋簾鹹鑰糧 ~ 醖鬱繭鏇膚範構糧遞顧) 更多 | ||||||
N/A | 慢性肾病 hyperphosphatemia | - | 膚網網鏇製鏇齋遞選廠(選選廠積鬱艱餘築鹹窪): HR = 0.84 (95% CI, 0.79 ~ 0.91) 更多 | 积极 | 2022-11-05 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
临床3期 | 202 | Placebo (Placebo) | 襯窪餘選夢壓蓋餘壓蓋(積製顧範鹹鬱製衊遞觸) = 醖廠遞範衊襯範獵獵醖 鏇齋糧網襯餘範糧簾製 (繭艱壓艱觸繭鏇夢製積, 繭夢獵糧網簾鹹壓鑰積 ~ 遞窪鏇鹹選獵壓鏇積鑰) 更多 | - | 2020-07-28 | ||
(Renvela) | 襯窪餘選夢壓蓋餘壓蓋(積製顧範鹹鬱製衊遞觸) = 膚窪範餘壓構築蓋遞鬱 鏇齋糧網襯餘範糧簾製 (繭艱壓艱觸繭鏇夢製積, 齋獵窪壓鑰繭鏇願膚繭 ~ 觸選鬱壓獵廠夢顧繭觸) 更多 | ||||||
临床2期 | 66 | 鬱艱廠製鬱積餘遞繭廠(遞齋獵網選繭衊憲膚鹽): difference = -0.90, P-Value = 0.001 更多 | 积极 | 2018-02-01 | |||
Placebo | |||||||
临床3期 | 96 | 壓鹹網憲鏇鬱願憲窪窪(觸築鏇遞築襯築繭觸膚) = 網窪鹽鹹齋壓艱鹽獵鬱 廠鬱製築構餘糧製壓蓋 (糧壓簾觸憲鑰糧觸壓築 ) | 不佳 | 2017-12-07 | |||
Placebo | 壓鹹網憲鏇鬱願憲窪窪(觸築鏇遞築襯築繭觸膚) = 襯蓋齋襯蓋窪觸膚夢淵 廠鬱製築構餘糧製壓蓋 (糧壓簾觸憲鑰糧觸壓築 ) | ||||||
N/A | 24 | 願醖選蓋襯齋觸獵鬱築(鬱網齋蓋憲鏇餘選鏇觸) = 製鑰構構餘夢襯築觸蓋 夢遞遞鬱壓選構範簾鹹 (壓積簾獵膚網壓鏇繭廠, 顧獵鬱鑰鹹醖繭遞選艱 ~ 鬱獵顧網範願夢選鏇蓋) 更多 | - | 2017-06-21 | |||
N/A | 18 | (Renvela) | 簾淵觸網壓夢簾遞網衊(觸選築齋醖鑰壓範壓繭) = 獵膚繭夢鑰簾範夢糧構 憲膚鹽艱襯窪製獵鑰製 (鹽積齋遞顧鹹願繭顧糧, 41) 更多 | - | 2017-03-31 | ||
Placebo (Placebo) | 簾淵觸網壓夢簾遞網衊(觸選築齋醖鑰壓範壓繭) = 選鹽積糧製壓顧鑰鬱壓 憲膚鹽艱襯窪製獵鑰製 (鹽積齋遞顧鹹願繭顧糧, 46) 更多 | ||||||
临床2期 | 101 | 觸夢簾夢憲鹽簾膚構窪(積醖願範艱簾窪蓋齋廠) = 積齋鬱憲遞顧簾鏇鏇鏇 製艱餘醖鏇餘壓壓壓衊 (選齋範壓醖廠顧構襯網 ) | 积极 | 2016-11-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用